Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives: An update of the Seattle experience

Transplantation

Volumn 61, Issue 1, 1996, Pages 54-61

  Wagner, John L ^a   Deeg, H Joachim ^a,b   Seidel, Kristy ^a   Anasetti, Claudio ^a,b   Doney, Kris ^a,b   Sanders, Jean ^a,c   Sullivan, Keith M ^a,b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN TISSUE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; UNITED STATES;

EID: 0030024546     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199601150-00012     Document Type: Article

References (34)

1. Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979; 53: 504.
2. McGlave PB, Haake R, Miller W, Kim T, Kersey J, Ramsay NKC. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. Blood 1987; 70: 1325.
3. Speck B, Gratwohl A, Nissen C, et al. Treatment of severe aplastic anemia. Exp Hematol 1986; 14: 126.
4. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994; 84: 941.
5. Doney K, Storb R, Appelbaum FR, et al. Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anemia. Br J Haematol 1993; 85: 182.
6. Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA Working Party. Br J Haematol 1988; 70: 177.
7. Doney K, Storb R, Buckner CD, et al. Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. Exp Hematol 1987; 15: 239.
8. Rothmann SA, Streeter RR, Bukowski RM, Hewlett JS. Treatment of severe aplastic anemia with antithymocyte globulin. Exp Hematol 1982; 10: 809.
9. Hinterberger-Fischer M, Hinterberger W, Hockern P, et al. Treatment of severe aplastic anemia with combined immunosuppression (antithymocyte globulin and high-dose methylprednisolone). Acta Haematol 1986; 76: 196.
10. de Planque MM, Bacigalupo A, Würsch A, et al. Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol 1989; 73: 121.
11. Doney KC, Pepe M, Storb R for the Seattle Bone Marrow Transplant Team. Comparison of bone marrow transplantation (BMT) to immunosuppressive therapy (IST) as primary treatment of acquired aplastic anemia (AA) [Abstract]. Exp Hematol 1993; 21: 1081.
12. Beatty PG, Di Bartolomeo P, Storb R, et al. Treatment of aplastic anemia with marrow grafts from related donors other than HLA genotypically-matched siblings. Clin Transplant 1987; 1: 117.
13. Sanders JE, Storb R, Anasetti C, et al. Marrow transplant experience for children with severe aplastic anemia. Am J Pediatr Hematol Oncol 1994; 16: 43.
14. Sanders JE, Flournoy N, Thomas ED, et al. Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. Med Pediatr Oncol 1985; 13: 165.
15. Storb R, Thomas ED, Weiden PL, et al. Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. Blood 1976; 48: 817.
16. Anasetti C, Martin PJ, Storb R, et al. Engraftment of allogeneic hematopoietic stem cells in patients conditioned only with anti-CD3 monoclonal antibody BC3 plus methylprednisolone. Blood 1994; 84 (suppl) : 249a.
17. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832.
18. Olerup O, Zetterquist H. HLA-DRB1*01 subtyping by allele-specific PCR amplification: a sensitive, specific and rapid technique. Tissue Antigens 1991; 37: 197.
19. Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269.
20. Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anemia: long-term follow-up of a controlled trial. Br J Haematol 1989; 72: 567.
21. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037.
22. Doney KC, Storb R, Beach K, et al. A phase I study of trimetrexate used in combination with cyclosporine as acute graft-versus-host-disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. Transplantation, in press.
23. Kennedy MS, Deeg HJ, Storb R, et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids and cyclosporine. Am J Med 1985; 78: 978.
24. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4: 42.
25. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295.
26. Pepe MS, Longton G, Pettinger M, Mori M, Fisher LD, Storb R. Summarizing data on survival, relapse, and chronic graft-versus-host disease after bone marrow transplantation: motivation for and description of new methods. Br J Haematol 1993; 83: 602.
27. Storb R, Weiden PL, Sullivan KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987; 70: 116.
28. Deeg HJ, Anasetti C, Storb R, et al. Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, -B, -DRB matched unrelated donors [Letter]. Blood 1994; 83: 3417.
29. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511.
30. Bacigalupo A, Van Lint MT, Congiu M, Marmont AM. Bone marrow transplantation (BMT) for severe aplastic anaemia (SAA) in Europe: a report of the EBMT-SAA Working Party. Bone Marrow Transplantation 1988; 3: 44.
31. Hows JM, Yin JL, Marsh J, et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood 1986; 68: 1322.
32. Bacigalupo A, Hows J, Gordon-Smith EC, et al. Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party. Bone Marrow Transplant 1988; 3: 531.
33. Camitta B, Ash R, Menitove J, et al. Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings. Blood 1989; 74: 1852.
34. Hows JM, Szydlo R, Anasetti C, Camitta B, Gajewsky J, Gluckman E. Unrelated donor marrow transplants for severe acquired aplastic anemia. Bone Marrow Transplant 1992; 10: 102.